Navigation Links
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Date:7/1/2009

of FSH activity. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of corifollitropin alfa may replace the first seven injections of rFSH preparation in a COS treatment cycle. The corifollitropin alfa regimen is being developed in a GnRH antagonist protocol. Corifollitropin alfa was filed in the European Union in late 2008.

Corifollitropin alfa Important Safety Information

The most frequently reported adverse drug reactions during treatment with corifollitropin alfa in clinical trials are Ovarian Hyperstimulation Syndrome (OHSS), pelvic pain and discomfort, headache, nausea, fatigue and breast complaints (including tenderness). They are reported with an incidence between 1% and 6%.

About Infertility

Infertility is a disease or condition that impairs the body's ability to perform the basic function of reproduction.(7) It is often diagnosed after a couple has not conceived after one year of unprotected, well-timed intercourse.(8) Women over the age of 35 are encouraged to seek diagnosis and treatment for infertility following six months of unprotected intercourse.(9) Around 15 percent of couples of reproductive age have a fertility problem.(8)

There are many causes of infertility including problems with the production of sperm or eggs, with the fallopian tubes or the uterus, endometriosis, frequent miscarriage, as well as hormonal and autoimmune (antibody) disorders in both men and women.(8)

With infertile couples, the source of infertility lies with the male in 40 percent of cases and 40 percent with the female. The remaining 20 percent is either a joint problem or unknown, because the cause has not been identified. There are a variety of treatments available for infertility; these include surgery, hormone treatments, insemination, IVF and natural treatments, among others.(8)

'/>"/>
SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 Nektar Therapeutics (Nasdaq: NKTR ... appointed to serve on its board of directors. ... with over 35 years of experience in corporate ... to Nektar extensive industry perspective at an important ... Robin, President and CEO of Nektar and member ...
(Date:12/14/2009)... - Results From a Survey Conducted by UCB Assessing ... Countries , , - A third of ... impacts their enjoyment of the festive season, ... shopping for gifts, preparing holiday ... difficult to do, - Nearly ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
(Date:12/11/2009)... Dec. 11 Ambit Biosciences Corporation announced today ... M. D. Anderson Cancer Center of the first patient ... E fficacy) Phase 2 pivotal trial ... (AML). AC220 is a novel, orally available, potent ... as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ...
Breaking Biology Technology:Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5
... with a one-two punch of an acquisition and a merger ... grow its GE Medical Systems division. But in ... giant to make additional acquisitions in order to own market ... bought into, according to a company spokesperson. , ,On Oct. ...
... business conditions provide a golden opportunity to tune your ... appear to have calmed, the long-term winners will be ... winning strategies. Real competitive advantage comes from making ... fundamentally aligning your talent management practice to that choice, ...
... still going on in the Midwest at places like the Maytag ... story on Monday. There are many experts giving opinions about why ... jobs are going overseas for cheaper wages and most stop there ... stop because many companies are so focused on the bottom line. ...
Other Biology Technology:GE Medicals Acquisitions May Prompt More Purchases 2GE Medicals Acquisitions May Prompt More Purchases 3Talent Constellations or Talent Communities Choosing the Right Talent 2Talent Constellations or Talent Communities Choosing the Right Talent 3Spend Money to Make Money and Dump Obsolete Tech Strategies 2Spend Money to Make Money and Dump Obsolete Tech Strategies 3Spend Money to Make Money and Dump Obsolete Tech Strategies 4
(Date:12/14/2009)... of an international team that has used DNA samples ... history of North America,s woolly mammoths and ancient horses. ... Atmospheric Sciences professor Duane Froese and his colleagues counters ... bones and teeth. That analysis concluded that more than ... ,megafauna,) disappeared about 13,000 years ago. , In ...
(Date:12/14/2009)... be transmitted by sneezing, touching, or for Tasmanian ... habit that may have driven the dinosaurs to extinction ... Upcroft, a member of f1000 Biology, highlights the ,paleobiological ... PLoS One. This led them to deduce that a ... bones seen in many tyrannosaurid fossils. , The parasite,s ...
(Date:12/14/2009)... team of researchers from the Astrobiology Centre (INTA-CSIC) has ... essential to the formation of the most basic biological ... In order to carry out this study, published in ... recreated the chemical conditions of the early Earth. , ... in ammoniac solutions it produces hydrogen cyanide, a substance ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2Mesa Labs Reports Higher First Quarter Earnings 54256 1Mesa Labs Reports Higher First Quarter Earnings 54256 2Mesa Labs Reports Higher First Quarter Earnings 54256 3Mesa Labs Reports Higher First Quarter Earnings 54256 4Mesa Labs Reports Higher First Quarter Earnings 54256 5Ohio Judge Rules Tobacco Settlement Funds Should Be Used as Intended to Reduce Tobacco Use and Save Lives 54255 1Ohio Judge Rules Tobacco Settlement Funds Should Be Used as Intended to Reduce Tobacco Use and Save Lives 54255 2Lifeline Vascular Access Launches New Platform for Physicians to Share Best Practices and Improve Vascular Access Care 54253 1Lifeline Vascular Access Launches New Platform for Physicians to Share Best Practices and Improve Vascular Access Care 54253 2
... A study by UC Irvine ecologists finds that ... an average of 20 percent, countering the belief that ... Faster plant growth means the tropics will take in ... effects are unclear. Over the next century, nitrogen pollution ...
... Biosensor and Imaging Center have developed new fluorogen ... component of novel molecular biosensor technology being created ... used to monitor biological activities of individual proteins ... time, are described in the February issue of ...
... Quest Product Development, teaming with,Ball Aerospace & ... successfully demonstrated a new thermal insulation. NASA has ... II grant to develop and,commercialize this advanced thermal ... NASA,s new,spacecraft and exploration missions would preserve rocket ...
Other Biology News:Nitrogen pollution boosts plant growth in tropics by 20 percent 2Carnegie Mellon scientists develop fluorescent proteins for live cell imaging, biosensor design 2Carnegie Mellon scientists develop fluorescent proteins for live cell imaging, biosensor design 3Colorado Engineering Firms Win NASA Grant to Develop Innovative Insulation for Next Generation Spacecraft - Super-Insulation May Allow Future Energy Efficient Appliances 2
BlotGel application pool -see Blotters (Semi-Dry) for more info...
... described by end-users to be "a delight ... of light microscopy and electronic imaging. With ... does not require much space and can ... environment. The DM-BA300 combines Motic's own revolutionary ...
Request Info...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
Biology Products: